Heplatinum Pharmaceutical-B announced that a new drug clinical trial application targeting thymic matrix lymphopoietin and HBM7575, a long-acting bispecific antibody with an undisclosed target, has been approved by the China National Drug Administration for the treatment of asthma. This bispecific antibody was developed by the company in collaboration with Sichuan Kelunbotai Biomedical Co., Ltd. Previously, the phase I clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis successfully completed the first patient administration.

Heplatinum Pharmaceutical-B announced that a new drug clinical trial application targeting thymic matrix lymphopoietin and HBM7575, a long-acting bispecific antibody with an undisclosed target, has been approved by the China National Drug Administration for the treatment of asthma. This bispecific antibody was developed by the company in collaboration with Sichuan Kelunbotai Biomedical Co., Ltd. Previously, the phase I clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis successfully completed the first patient administration.